SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Selecta Biosciences, Inc. (Nasdaq – SELB)

BALA CYNWYD – November 16, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Selecta Biosciences, Inc. (“Selecta Biosciences” or the “Company”) (Nasdaq – SELB) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the merger between the Company and Cartesian Therapeutics, Inc. (“Cartesian”) in an all-stock transaction. Under the terms of the merger agreement, at the effective time of the merger, securityholders of Cartesian will own approximately 73.1% of the combined company and securityholders of Selecta Biosciences will own approximately 26.9% of the combined company.

The investigation concerns whether the Selecta Biosciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.

If you own shares of Selecta Biosciences stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.